Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Identify the dividend Etf with the lowest tax drag and learn how tax drag affects net returns. Compare options quickly.
27,776 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
BYD expands beyond China with a strong EU push, a growing factory footprint, and a multi-region strategy that could r...
Goldman Sachs raises price targets on three major tech names by roughly 10%, reflecting improved growth visibility as...
A standout AI infrastructure stock is delivering blistering earnings growth in 2026, reshaping the investing landscap...
Pinterest stock is slipping mid-session, dropping around 6% to near $18.75 as peers like Meta and Snap show lighter d...
Iovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
With inflation stubborn and growth resilient, traders are debating whether the Fed will hold rates in June or pivot l...
Billionaire investor Bill Ackman points to SpaceX's durable cash-flow engines, highlighting a cornerstone of value as...
Investors are buzzing about a potential shift in how Rocket Lab does business. This article delves into what a SpaceX...
Nvidia remains the AI chip leader, but Broadcom and Marvell are gaining ground as hyperscalers push for lower costs t...
As Rocket Lab nears a pivotal earnings print, investors are quietly growing more bullish. This piece breaks down why ...
A major fund just boosted its stake in a struggling auto-parts retailer. This article breaks down what the move could...